Kestra Medical Technologies, Inc.

In case you missed it!

Beyond the Late Breaker: ACE-PAS investigators share perspectives on SCA risk, the role of WCDs, and redefining standard of care. Watch the full recording: https://hubs.ly/Q03SqzQ70

Beyond the Late Breaker  Join ACE-PAS study authors and leading clinical voices as they provide deeper insights, context and discussion following the #AHA25 presentation. This recorded session convenes authors and experts to expand on key findings from the largest prospective wearable cardioverter defibrillator (WCD) registry to date, exploring: ✅ Contemporary insights into sudden cardiac death (SCA).   ✅ The role of WCDs in bridging during guideline-directed titration and early heart failure care.  ✅ Advances in detection, compliance and patient experience.  Identification of clinically meaningful arrhythmias impacting care decisions.  ✅ Potential implications for future adoption, guideline considerations and the evolving standard of SCA management.    🔗 Learn more: https://hubs.li/Q03SpZNg0 Kestra Medical Technologies, Inc.

Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device KIRKLAND, Wash., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS), presented as a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. ACE-PAS, the largest prospective real-world study of wearable defibrillators to date, confirmed the strong safety and effectiveness of the ASSURE WCD in clinical practice. Read More → https://lnkd.in/gMbGTV2d

🚨 Mark your calendars. You won't want to miss this late-breaking presentation! 🚨 ✅ What: ACE-PAS Trial results ✅ Where: AHA Scientific Sessions 2025 ✅ When: Monday, November 10 at 8:44 AM | Session 211-213 ✅ Watch: https://lnkd.in/geeG-m-h #AHA25 #AHAScience

From wearable protection to real-time insights, the Cardiac Recovery System® platform is redefining the standard for SCA risk management. Visit booth 4617 to learn how: https://lnkd.in/g4i-s3xb #AHA25 #AHAScience

At #HFSA2025, Kestra showed how the Cardiac Recovery System® platform empowers confident care. Next up, we're in New Orleans at #AHA25. Visit booth 4617 to see the future of SCA risk management. #AHAScience https://lnkd.in/gy44MtMP

GDMT Takes Time. SCD Doesn’t Wait. Join us at AHA to discover how the Cardiac Recovery System® platform empowers providers and protects patients. https://lnkd.in/gAjHBJHm #AHA25 #AHAScience

MedAxiom is proud to announce a new industry partnership with Kestra Medical Technologies, Inc. — a leader in wearable medical devices and digital health solutions. Together, we’re working to enhance sudden cardiac arrest risk management and improve patient outcomes through innovative, connected care. Learn more: https://hubs.li/Q03RXwXj0 #MedAxiom #Partnership #Cardiology #DigitalHealth #Innovation #SuddenCardiacArrest #ConnectedCare